Andrew K. Moriarity

About

Andrew K. Moriarity is a health services researcher and urologic oncologist whose work focuses on improving the value and accuracy of cancer care delivery. His primary research areas include cost-effectiveness analysis, clinical pathway optimization, and diagnostic imaging for prostate cancer. Moriarity’s most influential contribution is his pioneering application of time-driven activity-based costing (TDABC) to prostate cancer treatment. In his highly cited 2015 study (144 citations), he provided the first detailed, phase-of-care cost breakdown for managing localized, low-risk prostate cancer, revealing significant short- and long-term cost variations across treatment modalities. This work has helped reshape how healthcare systems evaluate resource allocation and treatment value. He also critically assessed the limitations of modern imaging, including abdominopelvic CT and multiparametric MRI, for detecting lymph node metastases prior to radical prostatectomy (2020). By identifying diagnostic gaps, his research underscores the need for better staging tools to avoid unnecessary surgeries. Moriarity’s work bridges clinical urology and health economics, offering actionable insights for reducing costs while maintaining quality outcomes. His findings are widely referenced by policymakers and clinicians aiming to optimize prostate cancer care.

Research Focus

Key Achievements

Top Papers

1. 1
   Utilizing time‐driven activity‐based costing to understand the short‐ and long‐term costs of treating localized, low‐risk prostate cancer

   144 citations · 2015
2. 2
   Limitations of abdominopelvic CT and multiparametric MR imaging for detection of lymph node metastases prior to radical prostatectomy

   7 citations · 2020

Key Collaborators

Contact & Links